glp 1 iih Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension The Potentially Modifiable Risk Factor

While BPC-157 can be injected or orally consumed, the latter route may be associated with more targeted effects on the GI tract

Ongoing large-scale CVOTs will determine its effects on hard cardiovascular endpoints

FDA-approved indications and labeling The GLP-1 class includes drugs FDA-approved for type 2 diabetes (beginning with exenatide in 2005) and for chronic weight management liraglutide (Saxenda) in 2014, semaglutide (Wegovy) in 2021, and tirzepatide (Zepbound) in 2023

Is the peptide being used for the same indication that was studied

GLP-1 and semaglutide talk versus the broader peptide category Much of the online conversation centers on GLP-1 medications, with semaglutide being the name most people recognize